OncoMatch/Clinical Trials/NCT07488611
PROGAIN Trial in Gastric Cancer Surgery
Is NCT07488611 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Protein-enriched peripheral parenteral nutrition (Winuf A+ and Standard peripheral parenteral nutrition (Winuf for stomach (gastric) cancer.
Treatment: Protein-enriched peripheral parenteral nutrition (Winuf A+ · Standard peripheral parenteral nutrition (Winuf — This randomized study will evaluate whether protein-enriched parenteral nutrition improves early postoperative recovery in patients undergoing gastrectomy for gastric cancer. Participants will be assigned to receive either protein-enriched parenteral nutrition or standard parenteral nutrition during the perioperative period. The primary outcome is nitrogen balance on postoperative day 5. Secondary outcomes include postoperative complications, recovery of oral intake, and short-term changes in nutritional status and body composition.
Check if I qualifyExtracted eligibility criteria
Lab requirements
Kidney function
Serum Creatinine > 2 x ULN
Liver function
AST or ALT > 3 x ULN; Total Bilirubin > 3 x ULN
Patients with severe metabolic abnormalities confirmed by preoperative laboratory tests, including but not limited to: Triglyceride > 400 mg/dL; AST or ALT > 3 x ULN; Total Bilirubin > 3 x ULN; Serum Creatinine > 2 x ULN; HbA1c > 9.0%; Potassium < 3.0 mEq/L or > 6.0 mEq/L; Calcium > 12.5 mg/dL; Sodium > 155 mmol/L; Magnesium > 3.0 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify